台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

國光生

(4142)
可現股當沖
  • 股價
    27.50
  • 漲跌
    ▲0.20
  • 漲幅
    +0.73%
  • 成交量
    700
  • 產業
    上市 生技醫療類股
  • 635人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
國光生 (4142)籌碼相關-永豐金-五權 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

永豐金-五權 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2019/05/3100.00119.5519.50-11,614-0.06%
2019/05/30219.5000.0019.5021,6080.12%
2019/05/2900.00119.2019.35-11,595-0.06%
2019/05/23819.4500.0019.5581,5350.52%
2019/05/2200.00120.4020.45-11,430-0.07%
2019/05/2100.003020.3120.25-301,419-2.11%
2019/05/20220.0000.0020.2021,4130.14%
2019/05/1700.001720.7520.40-171,398-1.22%
2019/05/1500.00219.3819.30-21,359-0.15%
2019/05/1300.003419.5019.25-341,359-2.50%
2019/05/082119.49219.6319.65191,3541.40%
2019/05/03419.3500.0019.3041,3290.30%
2019/05/02419.4800.0019.4041,3080.31%
2019/04/29620.0700.0019.9061,2440.48%
2019/04/26120.3000.0020.3511,2210.08%
2019/04/25120.5000.0020.5011,2220.08%
2019/04/22620.8000.0020.7061,2100.50%
2019/04/18321.4500.0021.0031,1940.25%
2019/04/1700.001821.8121.95-181,165-1.54%
2019/04/16121.6500.0021.4511,1510.09%
2019/04/15421.702021.7521.75-161,132-1.41%
2019/04/12221.65521.9621.65-31,115-0.27%
2019/04/11322.3200.0022.5031,0480.29%
2019/04/10121.9000.0021.9519440.11%
2019/04/08220.2500.0020.2027630.26%
2019/04/0100.00121.1020.70-1746-0.13%
2019/03/29121.1500.0021.1017160.14%
2019/03/281920.401920.6720.4506950.00%
2019/03/27620.61119.9020.9556780.74%
2019/03/26119.9500.0019.9016390.16%
2019/03/22119.9000.0019.9016710.15%
2019/03/14520.0000.0019.9556890.73%
2019/03/08219.9500.0019.9527750.26%
2019/03/05220.0000.0020.0029280.22%
2019/02/27220.2000.0020.1529480.21%
2019/02/261120.3400.0020.25119501.16%
2019/02/25519.9500.0019.9059530.52%
2019/02/1200.001019.9519.95-101,134-0.88%
2019/01/281020.1500.0020.00101,1740.85%
2019/01/23219.90619.9719.90-41,264-0.32%
2019/01/0900.00120.7520.40-11,954-0.05%
2019/01/0800.00220.6320.60-22,024-0.10%
2019/01/0200.00220.1520.00-22,630-0.08%
2018/12/2800.00220.0020.30-22,806-0.07%
2018/12/25120.4000.0020.0513,2470.03%
2018/12/24220.7500.0020.6523,4840.06%
2018/12/20120.8500.0020.6513,7210.03%
2018/12/1900.00521.4021.20-53,712-0.13%
2018/12/18321.5200.0021.4533,7150.08%
2018/12/1700.00121.8522.20-13,710-0.03%
2018/12/14921.2400.0021.2093,6970.24%
2018/12/10521.43721.8021.35-23,826-0.05%
2018/12/0700.00621.8021.75-63,912-0.15%
2018/12/06321.70322.6521.8003,9760.00%
2018/12/0300.00122.8522.80-13,917-0.03%
2018/11/27320.7500.0020.9033,7100.08%
2018/11/2600.00520.5320.45-53,690-0.14%
2018/11/23120.4000.0020.4013,6830.03%
2018/11/22120.7000.0020.7013,6700.03%
2018/11/21321.1500.0021.0033,6550.08%
2018/11/19621.5300.0021.6063,6280.17%
2018/11/16221.50521.7521.50-33,615-0.08%
2018/11/15521.45521.7521.3503,6030.00%
2018/11/13321.9300.0022.1033,5660.08%
2018/11/12221.65121.9521.6013,5300.03%
2018/11/09222.151021.9322.35-83,482-0.23%
2018/11/06420.7800.0020.3043,3940.12%
2018/11/05821.11121.3521.0573,3810.21%
2018/11/01121.05121.5521.4003,3420.00%
2018/10/3100.00120.3020.30-13,308-0.03%
2018/10/30219.73320.1520.30-13,291-0.03%
2018/10/29122.0500.0021.6013,2300.03%
2018/10/26822.41422.4522.4043,1910.13%
2018/10/25621.6000.0021.3063,1360.19%
2018/10/241123.1000.0023.00113,0870.36%
2018/10/23224.2800.0024.0523,0360.07%
2018/10/2200.00124.6524.55-13,010-0.03%
2018/10/19324.92225.2024.7013,0170.03%
2018/10/18226.18226.7325.7503,0130.00%
2018/10/1700.00524.9024.95-52,981-0.17%
2018/10/16524.1000.0024.0552,9900.17%
2018/10/1500.00224.5524.55-22,910-0.07%
2018/10/12625.78725.8625.30-12,825-0.04%
2018/10/11923.7800.0025.0092,6520.34%
2018/10/0910325.0300.0026.151032,4684.17% 大買/鉅額交易
2018/10/0800.001625.1726.30-162,274-0.70%
2018/10/05423.31423.4424.3502,0970.00%
2018/10/04223.90324.0024.00-11,978-0.05%
2018/10/031024.3800.0024.90101,8940.53%
2018/10/0200.001523.9724.50-151,635-0.92%
2018/10/01521.971822.8122.95-131,382-0.94%
2018/09/28219.70520.4020.90-31,173-0.26%
2018/09/27419.6300.0019.7541,1530.35%
2018/09/26119.6000.0019.6511,1530.09%
2018/09/18220.50820.7520.60-61,089-0.55%
2018/09/17219.081319.0019.05-111,014-1.08%
2018/09/14319.70120.0019.6529930.20%
2018/09/12220.751220.7520.75-10863-1.16%
2018/09/10517.9900.0018.0057780.64%
2018/09/05218.2000.0018.2527790.26%
2018/09/04118.2000.0018.2517860.13%
2018/09/03118.3000.0018.2017920.13%
2018/08/27218.2500.0018.3028090.25%
2018/08/23218.2500.0018.4028110.25%
2018/08/22518.6500.0018.7058170.61%
2018/08/1300.00118.9018.80-1833-0.12%
2018/08/09419.2500.0019.2548140.49%
2018/08/07119.8500.0019.7518060.12%
2018/08/03720.0900.0019.9577920.88%
2018/07/2700.00119.2019.20-1721-0.14%
2018/07/2500.00420.5020.35-4660-0.61%
2018/07/24120.5000.0020.0015870.17%
2018/07/2300.00619.0519.25-6463-1.29%
2018/07/03317.7000.0017.7035550.54%
2018/06/1500.00319.3019.20-3694-0.43%
2018/06/1200.00119.5019.50-1691-0.14%
2018/06/05119.4000.0019.3017290.14%
2018/05/2900.00419.0519.25-4780-0.51%
2018/05/2500.00119.1019.30-1776-0.13%
2018/05/24119.2000.0019.2517790.13%
2018/05/22418.7500.0018.5047570.53%
2018/05/1500.00318.1518.15-3778-0.39%
2018/05/1400.00218.2018.15-2796-0.25%
2018/05/11318.4500.0018.2537980.38%
2018/04/2500.00319.6519.50-3795-0.38%
2018/04/13319.1500.0019.1539370.32%
2018/04/1000.00820.5820.00-8918-0.87%
2018/04/09920.21820.2021.0018990.11%
2018/04/03219.90120.1019.7518290.12%
2018/04/0200.00619.3019.20-6760-0.79%
2018/03/31619.2900.0019.1067560.79%
2018/03/2700.00419.8519.50-4736-0.54%
2018/03/2600.00219.3819.20-2747-0.27%
2018/03/2300.001019.1019.00-10743-1.34%
2018/03/22219.50319.8519.50-1740-0.14%
2018/03/2100.00219.8519.75-2742-0.27%
2018/03/2000.00319.8019.75-3743-0.40%
2018/03/19119.8000.0019.7517450.13%
2018/03/15119.9000.0019.9517540.13%
2018/02/2700.00318.7518.70-3736-0.41%
2018/02/26318.9000.0018.7537370.41%
2018/02/09117.9000.0017.9017450.13%
2018/02/05219.65319.7819.65-1735-0.14%
2018/02/011020.2500.0020.20107381.35%
2018/01/291020.3500.0020.30107461.34%
2018/01/1600.00421.3021.10-4905-0.44%
2018/01/1500.00220.5820.55-2875-0.23%
2018/01/09120.5000.0020.4019310.11%
2018/01/0200.00120.1520.05-11,049-0.10%
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-2024/03/13
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章